Given increased galectin-3 expression levels in adipose tissues and circulating monocytes as well as elevated galectin-3 serum levels in the obese [39,65,66] (Figure 1), a heightened interest in the pathological functions of galectin-3 in obesity-associated diseases, such as type 2 diabetes and MAFLD, has developed in recent years [67,68]. The gene discussed is LGALS3; the disease is type 2 diabetes mellitus.